The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a huge mover today! About 679,016 shares traded hands or 20.42% up from the average. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 0.93% since April 4, 2016 and is uptrending. It has underperformed by 0.16% the S&P500.
The move comes after 8 months positive chart setup for the $891.44M company. It was reported on Nov, 4 by Barchart.com. We have $35.02 PT which if reached, will make NASDAQ:AMAG worth $320.92 million more.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage
Out of 6 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. AMAG Pharmaceuticals has been the topic of 16 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Jefferies on Thursday, August 11. The rating was initiated by Needham on Thursday, October 27 with “Buy”. The company was downgraded on Wednesday, August 19 by Zacks. The firm earned “Equal-Weight” rating on Thursday, January 21 by Barclays Capital. The rating was downgraded by Raymond James to “Market Perform” on Wednesday, May 4. The rating was reinitiated by Deutsche Bank with “Hold” on Thursday, September 3. Leerink Swann maintained the stock with “Outperform” rating in Wednesday, May 4 report. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Buy” rating given on Tuesday, August 18 by Jefferies. The firm earned “Hold” rating on Thursday, November 19 by Deutsche Bank. The stock has “Outperform” rating given by Raymond James on Tuesday, September 1.
According to Zacks Investment Research, “AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.CombidexÂ®, the company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.”
Insitutional Activity: The institutional sentiment decreased to 0.83 in 2016 Q2. Its down 0.79, from 1.62 in 2016Q1. The ratio dived, as 33 funds sold all AMAG Pharmaceuticals, Inc. shares owned while 51 reduced positions. 15 funds bought stakes while 55 increased positions. They now own 42.73 million shares or 1.35% more from 42.16 million shares in 2016Q1.
Blackrock Institutional Commerce Na has invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Acadian Asset Mngmt Limited Company has 0% invested in the company for 3,743 shares. Pinebridge Invs Lp accumulated 4,245 shares or 0.01% of the stock. Wells Fargo And Commerce Mn has 0% invested in the company for 91,538 shares. Fmr Limited Liability Corporation last reported 4.15M shares in the company. Moreover, State Street Corp has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 1.85M shares. Credit Suisse Ag has invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Moreover, Nationwide Fund has 0.01% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 58,762 shares. Panagora Asset Mngmt has invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). The New York-based Alliancebernstein L P has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). California Public Employees Retirement Sys owns 95,100 shares or 0% of their US portfolio. Public Sector Pension Inv Board holds 0.01% or 24,700 shares in its portfolio. Metropolitan Life Com Ny has 24,140 shares for 0% of their US portfolio. Prudential Financial holds 0.02% or 442,877 shares in its portfolio. Blackrock Mngmt Lc, a New Jersey-based fund reported 153,490 shares.
Insider Transactions: Since October 20, 2016, the stock had 0 insider buys, and 1 insider sale for $122,462 net activity. $122,462 worth of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares were sold by Krop Julie.
More news for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) were recently published by: Fool.com, which released: “Why AMAG Pharmaceuticals, Inc. Is Tanking Today” on August 10, 2016. Fool.com‘s article titled: “Why AMAG Pharmaceuticals, Inc. Plunged 19.2% in May” and published on June 12, 2016 is yet another important article.
AMAG Company Profile
AMAG Pharmaceuticals, Inc., incorporated on November 9, 1981, is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of services and products for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Firm has a portfolio of services and products with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.